These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9289398)

  • 1. New therapeutic strategies for higher cure rates: high dose therapy and new therapeutic modalities. Proceedings of the 12th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium. Nagoya, Japan, 4-5 October 1996.
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S1-118. PubMed ID: 9289398
    [No Abstract]   [Full Text] [Related]  

  • 2. The 11th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium. Cytokines and New Anticancer Agents on the Horizon of Oncology. Nagoya, Japan, 24-25 November 1995.
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S1-119. PubMed ID: 8777775
    [No Abstract]   [Full Text] [Related]  

  • 3. New concepts of treatment strategies for hormone-related cancer. Proceedings of the 20th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium. March 11-12, 2005. Nagoya, Japan.
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():1-99. PubMed ID: 16273362
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges in Cancer Metastasis. Proceedings of the 14th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium. Nagoya, Japan, 11-12 September 1998.
    Cancer Chemother Pharmacol; 1999; 43 Suppl():S1-103. PubMed ID: 10375280
    [No Abstract]   [Full Text] [Related]  

  • 5. State of the art for digestive organs. Proceedings of the 19th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium. November 14-15, 2003. Nagoya, Japan.
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S1-90. PubMed ID: 15614933
    [No Abstract]   [Full Text] [Related]  

  • 6. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMS-247550 Bristol-Myers Squibb/GBF.
    Lin N; Brakora K; Seiden M
    Curr Opin Investig Drugs; 2003 Jun; 4(6):746-56. PubMed ID: 12901236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An example of the effects of drug resistance on the optimal schedule for a single drug in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1995; 12(1):55-69. PubMed ID: 7594878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 10. [San Antonio Breast Cancer Symposium 2003. New therapeutic prospects in the treatment of early-stage breast cancer].
    Montemurro F
    Tumori; 2004; 90(1):suppl 1-16. PubMed ID: 15143995
    [No Abstract]   [Full Text] [Related]  

  • 11. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BMS-310705 Bristol-Myers Squibb/GBF.
    Kolman A
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1292-7. PubMed ID: 15648951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic failure of antineoplastic agents. Extracellular and cellular causes].
    Hofsli E
    Tidsskr Nor Laegeforen; 1991 Jan; 111(1):37-40. PubMed ID: 2000585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 8th International Conference on Chemical Modifiers of Cancer Treatment. Part 2. Symposium proceedings. Kyoto, Japan, June 16-19, 1993.
    Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):419-638. PubMed ID: 7911793
    [No Abstract]   [Full Text] [Related]  

  • 15. AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 1.
    Walker K; Padhiar M
    IDrugs; 2010 Jan; 13(1):7-9. PubMed ID: 20024838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
    Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
    J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience.
    Berman D; Korman A; Peck R; Feltquate D; Lonberg N; Canetta R
    Pharmacol Ther; 2015 Apr; 148():132-53. PubMed ID: 25476108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIMECS 07 - Sixth AFMC International Medicinal Chemistry Symposium: recent approaches in anticancer therapy.
    Valla V
    IDrugs; 2007 Sep; 10(9):614-7. PubMed ID: 17786841
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.